Sanofi and Voluntis to deliver global mobile app for type 2 diabetes

15 March 2017

Sanofi (Euronext: SAN) and software designer Voluntis have announced a global alliance to deliver digital insulin titration solutions featuring a mobile phone application for type 2 diabetes patients treated with basal insulin to help with self-management and enable remote monitoring by healthcare teams.

The agreement reinforces the existing alliance between the two French companies, established in 2011, by expanding both its scope and geography. It will leverage the pharma major’s expertise in bringing innovative treatments to people living with diabetes and Voluntis' experience in creating companion software.

"Despite the availability of new medicines for diabetes, we see that outcomes are not sufficiently improving and that more than half of patients are not well-controlled"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK